Mozobil

Plerixafor in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to peripheral blood for collection and autologous transfusion in patients with lymphoma or multiple myeloma.

Plerixafor reversibly blocks the chemokine receptor CXCR4 to prevent binding of its ligand CXCL12 (stromal cell-derived factor-1α).

The drug is injected after four days of treatment with granulocyte-colony stimulating factor (G-CSF), 6-11 hours before initiation of apheresis. Following administration, both haematopoietic progenitor cells and mature leukocytes appear in the systemic circulation.

View Mozobil drug record

Further information: Genzyme

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

MIMS supplement on asthma and COPD

MIMS supplement on asthma and COPD

The June issue of MIMS includes a special supplement...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New antiviral treatment cuts COVID-19 mortality

New antiviral treatment cuts COVID-19 mortality

A combination of two monoclonal antibodies significantly...